Expensive new leukemia medication to be covered by Medicare

Share this content:
Medicare Will Cover Expensive New Leukemia Medication
Medicare Will Cover Expensive New Leukemia Medication

(HealthDay News) -- Medicare will pay for a new, expensive cancer medication that costs about $178,000 for a standard course of treatment, the Obama administration says.

Beginning Oct. 1, Medicare will make additional payments for patients with a particularly aggressive type of leukemia to receive Amgen's Blincyto (blinatumomab), The New York Times reported.

The announcement reverses a preliminary decision in April, when the government said Medicare would not pay extra for Blincyto because clinical studies were "not sufficient to demonstrate" that it offered substantial benefits to patients with acute lymphoblastic leukemia. However, the final rule to be published in the Federal Register on Aug. 17 says the administration received "additional information and input" from Amgen and other experts and now agrees with their opinion, The Times reported.

That means that Blincyto qualifies for special "add-on payments" that Medicare makes to hospitals for new treatments whose costs are not yet included in standard lump-sum payments for treating patients with a particular health problem.

Health Highlights: Aug 10, 2015

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs